

# KOBO BIOTECH LIMITED

Corp. Office: Unit 503/505, Hyde Park, Saki Vihar Road,  
Opp. Ansa Industrial Estate, Andheri (E), Mumbai - 400 072  
E-mail: info@kobobiotech.com • Website : www.avonlifesciences.com  
(CIN : L24110TG1993PLC016112)

---

Asst. General Manager,  
Dept. of Corporate Services.  
Bombay Stock Exchange Limited,  
14th Floor, P.J.Towers, Dalal Street, Fort,  
Mumbai: 400 001

13<sup>th</sup> February, 2023

**Dear Sir/ Madam,**

**Scrip Name: Kobo Biotech Limited, Scrip Code: 531541**

**Sub: OUTCOME OF THE BOARD MEETING: Unaudited Financial results for the Quarter and Nine months ended 31<sup>st</sup> December, 2022.**

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Monday, 13<sup>th</sup> February, 2023 inter alia approved the Unaudited Financial Results of the Company for the quarter and nine month ended 31<sup>st</sup> December, 2022 alongwith the Limited review report of statutory auditor thereon.

Please find enclosed a copy of the unaudited Financials along with Limited Review report from the Statutory Auditors.

The above-referred meeting was commenced at 3:00 p.m. and concluded at 04:15 p.m.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

Thank you,  
**For Kobo Biotech Limited**

**Jignesh Patel**  
**Company Secretary**

**KOBO BIOTECH LIMITED**  
CIN: L24110TG1993PLC016112

Corp. Office : H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400 072  
Regd. Office: Plot No. 121A/1, Western Hills, Addagutta Society, Opp. JNTU, Kukatpally, Hyderabad - 500072  
Statement of Unaudited Financial Results for the quarter and Nine Month ended 31st December, 2022

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations	0.00	0.00	0.00	0.00	0.00	0.00
II	Other Income	0.00	0.00	0.00	1.52	1.66	1.66
III	<b>Total Income (I+II)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>1.52</b>	<b>1.66</b>	<b>1.66</b>
IV	<b>Expenditure</b>						
	(a) Cost of raw material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Employee benefits expense	5.50	6.04	10.98	16.99	66.01	71.54
	(d) Finance Cost	0.00	0.00	0.01	0.00	13.46	13.47
	(e) Depreciation and Amortisation expenses	102.53	89.24	104.35	306.89	342.47	460.60
	(f) Exchange (Gain)/Loss	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other Expenses	11.07	14.93	19.50	53.64	60.65	978.64
	<b>Total Expenses</b>	<b>119.10</b>	<b>110.21</b>	<b>134.84</b>	<b>377.52</b>	<b>482.59</b>	<b>1,524.25</b>
V	<b>Profit/(Loss) before Exceptional Items and Tax (III-IV)</b>	<b>(119.10)</b>	<b>(110.21)</b>	<b>(134.84)</b>	<b>(376.00)</b>	<b>(480.93)</b>	<b>(1,522.59)</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) before Tax (V-VI)</b>	<b>(119.10)</b>	<b>(110.21)</b>	<b>(134.84)</b>	<b>(376.00)</b>	<b>(480.93)</b>	<b>(1,522.59)</b>
VIII	Tax expenses						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Net Profit/(Loss) after tax (VII-VIII)</b>	<b>(119.10)</b>	<b>(110.21)</b>	<b>(134.84)</b>	<b>(376.00)</b>	<b>(480.93)</b>	<b>(1,522.59)</b>
X	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>(119.10)</b>	<b>(110.21)</b>	<b>(134.84)</b>	<b>(376.00)</b>	<b>(480.93)</b>	<b>(1,522.59)</b>
XII	Paid-up equity share capital	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50
XIII	Other Equity	-	-	-	-	-	(14,625.31)
XIV	<b>Earnings (Loss) Per Share (Basic and Diluted) (In Rs.)</b>	<b>(0.50)</b>	<b>(0.46)</b>	<b>(0.57)</b>	<b>(1.58)</b>	<b>(2.02)</b>	<b>(6.39)</b>
	Notes :						

Notes:

	Notes :
1	The above unaudited standalone financial results, prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th February, 2023.
2	The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs.
3	Due to no operational activities at the Company for the past few years, the Employee benefit expenses for the quarter is considered only for the Employees who are reporting to work. Similarly, the interest cost for the quarter is not being provided for, as majority of the loans have been assigned to a leading ARC and for the remainder of the secured loans, the company is under discussion with the other lender for settlement.
4	The number of investor complaints at the beginning and pending at the end of the Quarter were Nil.
5	Figures for the quarter ended 31st March are the balancing figures between the audited figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year, which were subjected to limited review.
6	Figures of the previous periods have been regrouped / rearranged wherever considered necessary.

By order of the Board  
For Kobo Biotech Limited



Ajit Kamath  
Director

Mumbai  
13-Feb-23



**A N Shah & Associates**  
Chartered Accountants

C/303, Anand Nagar,  
Forjett Street,  
Opp. Bhatia Hospital,  
Mumbai – 400 036.  
Tel: +91 22 4976 9085

**Limited Review Report of Un-audited Financial Results of Kobo Biotech Limited**

**Independent Auditor's Review Report on Quarter ended Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To the Board of Directors of  
**Kobo Biotech Limited**  
Mumbai.

**Report on the Statement of Unaudited Financial Results**

We have reviewed the accompanying statement of unaudited financial results of **Kobo Biotech Limited** ("the Company") for the quarter and nine months ended December 31, 2022, which are included in the accompanying Statement of Unaudited Financial Results for the quarter and nine months ended December 31, 2022 ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations, 2015"), including relevant circulars issued by the SEBI from time to time. We have initialed the Statement for identification Purposes only. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

In our opinion and to the best of our information and according to the explanations given to us

**A N Shah & Associates**  
Chartered Accountants

C/303, 3<sup>rd</sup> Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.  
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158  
Email id: ca.akashshah3033@gmail.com



**A N Shah & Associates**  
Chartered Accountants

C/303, Anand Nagar,  
Forjett Street,  
Opp. Bhatia Hospital,  
Mumbai – 400 036.  
Tel: +91 22 4976 9085

these financial results:

- (i) Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015; and
- (ii) Give a true and fair view in conformity with the aforesaid accounting standards and other accounting principles generally accepted in India of the net Loss and other financial information of the company for the quarter ended 31<sup>st</sup> December, 2022.

**For,**  
**A N Shah & Associates,**  
**Chartered Accountants**

Akash  
Nilesh  
Shah

Digitally signed by  
Akash Nilesh Shah  
DN: cn=Akash Nilesh  
Shah, c=IN, o=Personal  
Reason: I am the author  
of this document  
Date: 2023-02-12  
15:46+05:30

**Akash Shah**  
**Proprietor**

**Date: 11 February, 2023**  
**Place: Mumbai**  
**UDIN: 23191340BGSPWZ9154**

**A N Shah & Associates**  
**Chartered Accountants**

C/303, 3<sup>rd</sup> Floor, Anand Nagar, Forjett Street, opposite Bhatia Hospital, Mumbai – 400 036.  
Landline No: +91 22 4976 9085, Mobile - +91 96190 40158  
Email id: ca.akashshah3033@gmail.com